Royalty Report: Drugs, cardiac, Delivery – Collection: 291171

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • cardiac
  • Delivery
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 291171

License Grant
Irish Licensor hereby grants to Licensee for the Term an exclusive license to the Licensor Intellectual Property to import, use, offer for sale and sell the Product in the Field in the Territory.
License Property
Product means the once or twice-daily oral tablet or oral capsule formulation(s) incorporating the Licensor Technology and containing the Compound as its sole active combination of ingredients, being developed pursuant to the R&D Program.

Licensor Intellectual Property means the Licensor Know-How, the Licensor Patents, the Licensor Improvements and the Product Patents.

Licensor Patents means any and all Patent Rights now existing, currently pending or hereafter filed by Licensor relating to the Licensor Technology.

Licensor Technology means the SODASâ oral controlled release formulation technology that comprises the formation of 0.5-5mm beads containing an active agent and excipients which can be coated with a product-specific modified release polymer and then formulated into a final formulation such as a sprinkle, a tablet or a capsule, as applied in the Licensor Know-How.

Licensor Trademark means SODAS® or such other trade marks as Licensor may from time to time reasonably specify.

Licensor Improvements means any and all improvements to the Licensor Patents, the Licensor Know-How, the Licensor Technology and/or the Product Patents that have been conceived, created, developed and/or otherwise invented by Licensor and/or Licensee under the R&D Program, or otherwise pursuant to this Agreement.

Patent Rights means any and all rights under any and all patent applications and/or issued or granted patents, now existing, currently pending or hereafter filed, including, but not limited to, provisional applications, substitutions, divisionals, continuations, continuations-in-part, renewals and any foreign counterparts thereof or equivalents thereto, including the right to claim priority from any of the foregoing under the Paris Convention, and all patents issuing or granted on any of the foregoing, and any foreign counterparts thereof, together with all registrations, reissues, re-examinations, supplemental protection certificates, or extensions thereof, and any foreign counterparts thereof, or any other government-issued rights substantially equivalent to the foregoing.

BiDil means the existing immediate release product containing the Compound that is currently marketed in the United States by Licensee.

Compound means the combination of the active drug substances isosorbide dinitrate and hydralazine HCl and/or other salts, bases and isomeric forms of each.

Field of Use
The know-how and technology is to develop a once-a-day version of its BiDil heart drug.

IPSCIO Record ID: 319167

License Grant
By this amended and restated agreement, the Parties are modifying their current relationship as of the Effective Date and have agreed to amend and restate the Original License and Distribution Agreement as set forth herein.

Licensor grants a limited license, under the Adderall XR Intellectual Property and under any and all statutory and regulatory exclusivities to Manufacture, have Manufactured and Market Impax Product in the Territory on and after the License Effective Date.

Licensor authorizes Licensee to Market Licensees AG Product in the Territory from and after the License Effective Date. In connection with and solely for purposes of such authorization,  Licensor grants a limited license under the Adderall XR Intellectual Property and under any and all statutory and regulatory exclusivities to Market such Licensee AG Product in the Territory from and after the License Effective Date.

The Authorization and License shall be on an Exclusive basis.

License Property
Adderall XR shall mean the pharmaceutical product that contains the Compound as its sole active ingredient which is approved for Marketing in the Territory pursuant to Shires NDA and sold under the trade name Adderall XR.

Adderall XR Intellectual Property shall mean
(i) U. S. Patent Nos. 6,322,819, 6,605,300, and 6,913,768 and any patent that issues as a result of a reexamination or reissue thereof;
(ii) any patent that issues from, or from any continuation, continuation-in-part or divisional application relating to, U.S. Patent Application Serial Nos. 09/176,542, 10/353,073, 10/758,417, 10/774,697, and 11/030,174; and
(iii) any other present or future U.S. patent owned or controlled by Licensor which may read upon the making, using, selling or importing of a Generic Product.

AG Product shall mean generically Labeled Adderall XR, commonly called an authorized generic product, approved for sale by the FDA pursuant to a labeling supplement to Licensors NDA.

Compound shall mean mixed amphetamine salts.

Adderall XR is combination medication used to treat attention deficit hyperactivity disorder – ADHD. It works by changing the amounts of certain natural substances in the brain. Amphetamine/dextroamphetamine belongs to a class of drugs known as stimulants.

Field of Use
Amphetamine/dextroamphetamine belongs to a class of drugs known as stimulants. It can help increase your ability to pay attention, stay focused on an activity, and control behavior problems. It may also help you to organize your tasks and improve listening skills.

IPSCIO Record ID: 240585

License Grant
The Parties have agreed to collaborate together in order to develop, improve, and commercialize therapeutics for the treatment of cardiovascular disease based upon Licensors proprietary technology.

Licensor, an individual, grants an exclusive, worldwide right and license during the term of this Agreement under all of Licensors rights in the Patent Rights and Technical Information to make, have made, use, have used, sell, have sold, and import, Collaboration Products.

License Property
Licensor has developed certain proprietary technology related to the combination of hydralazine and isosorbide dinitrate for the treatment of cardiovascular disease.

The patent is for Method of Reducing Mortality Associated with Congestive Heart Failure Using 1-Hydralazine and Isosorbide Dinitrate.

Field of Use
The field shall mean the combination of hydralazine and isosorbide dinitrate, with or without one or more additional active ingredients for the treatment of cardiovascular diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.